BEIJING, June 22, 2011 /PRNewswire-Asia-FirstCall/ — China
Medical Technologies, Inc. (the “Company”) (Nasdaq:
CMED), a leading China-based advanced in-vitro diagnostic
(“IVD”) company, today announced that its wholly-owned subsidiary,
Beijing GP Medical Technologies Co., Ltd. (“GP Medical”), has
entered into a strategic collaboration with Gaoxin Da An Healthcare
Investment Ltd. (“Da An Health”) to co-market and promote molecular
diagnostic technologies for clinical diagnostic applications in
China. The two parties will also work together to develop new
molecular diagnostic products to cater for Da An Health’s hospital
customers and leverage Da An Health’s independent laboratory
network for new product validation.
Under the agreement, GP Medical and Da An Health will promote
and offer the use of GP Medical’s molecular diagnostic products to
the customer base of Da An Health. As a result, GP Medical’s
existing direct sales network covering large hospitals will be
expanded to the customer network of Da An Health covering some of
the large hospitals that GP Medical did not cover, and large number
of mid and small-sized hospitals as well as community hospitals
through this strategic collaboration. In addition, the two parties
will jointly develop innovative molecular diagnostic product
packages or solutions to offer to Da An Health hospital customers.
The new product packages or solutions will be validated at the
independent laboratories of Da An Health. During the term of the
collaboration, the two parties can expand the scope from the
molecular diagnostic products to the full product lines of GP
Medical and its affiliates in the future.
“We are pleased to establish this strategic collaboration with
Da An Health,” commented Mr. Xiaodong Wu, Chairman and Chief
Executive Officer of the Company. “We believe this collaboration
will promote our brand name as well as product
‘/>”/>
